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Abstract
In March 2019, the US Food and Drug Administration (FDA) approved a nasal spray formu-
lation of esketamine for the treatment of resistant depression in adults. Esketamine is the
S-enantiomer of ketamine, an FDA-approved anaesthetic, known to cause dissociation and,
occasionally, hallucinations. While ketamine has not been approved for depression in the
USA or in any other country, it has been used off-label in cases of severe depression. This
commentary critically reviewed the evidence on esketamine submitted to the FDA, aiming
to draw implications for clinical practice, research and regulatory science.
In March 2019, the US Food and Drug Administration (FDA) approved a nasal spray formu-
lation of esketamine for the treatment of resistant depression in adults. Treatment-resistant
depression (TRD) refers to a depressive episode with inadequate response to at least two anti-
depressant (AD) trials of adequate doses and duration. According to the FDA label, esketa-
mine is indicated in TRD in association with AD treatment. This new drug has been under
review by the European Medicine Agency (EMA) for approval and licensing, and received a
positive feedback and may be soon available for clinical use also in European countries.
Esketamine is the S-enantiomer of ketamine, an FDA-approved anaesthetic. While keta-
mine has not been approved for depression in the USA or in any other country, it has been
used off-label in cases of severe depression (Daly and Singh, 2018; Popova et al., 2019;
Zhang and Hashimoto, 2019). However, ketamine is used for recreational purposes because
it produces desired mental and behavioural changes, such as euphoria, and perceptual changes,
such as dissociation and, occasionally, hallucinations (Caddy et al., 2015). These effects,
together with a risk of abuse and misuse, made ketamine a widespread street drug, also
known as ‘Special K’ (Zhu et al., 2016).
Against this background, in this commentary, the evidence on esketamine submitted to the
FDA was reviewed, aiming to draw implications for clinical practice, research and regulatory
science. The FDA website was searched using the term ‘esketamine’ (up to June 2019), and all
documents were downloaded and independently inspected by two investigators. Phase III
studies were identified and, using standard Cochrane meta-analytical methods (Higgins and
Green, 2011), efficacy and acceptability data were extracted and re-analysed.
Critical inspection of the FDA documentation revealed a total of four phase III trials
(Ochs-Ross et. al., 2019; Daly et al., 2019; Fedgchin et al., 2019; Popova et al., 2019). Three
were short-term placebo-controlled efficacy trials conducted in participants suffering from
TRD. The main characteristics of the three efficacy studies are summarised in Table 1.
TRANSFORM-2 is the only short-term efficacy trial that found a significant difference
between esketamine + AD and placebo + AD. This trial showed that participants receiving
esketamine had a reduction of 21.4 points at the Montgomery–Asberg Depression Rating
Scale (MADRS) (standard deviation (S.D.) 12.32) v. a reduction of 17.0 (S.D. 13.88) in the pla-
cebo group at day 28, with a mean difference between the two groups of 4.4 points.
TRANSFORM-1 and TRANSFORM-3 failed to show a significant difference in terms of effi-
cacy between esketamine + AD and placebo + AD.
The fourth study is a withdrawal placebo-controlled clinical trial (SUSTAIN-1,
NCT02493868) (Daly et al., 2019). A total of 297 patients who achieved stable remission or
stable response (without remission) with esketamine + AD were randomised to continue
esketamine + AD (N = 152) or continue AD and switch esketamine to placebo nasal spray
(N = 145). The primary outcome was time to relapse (Daly et al., 2019). Compared with
AD + placebo, AD + esketamine decreased the risk of relapse by 51% (hazard ratio (HR) =
0.49; 95% confidence interval (CI) 0.29–0.84) in patients who had achieved stable remission,
and 70% (HR = 0.30; 95% CI 0.16–0.55) in those who had achieved stable response.
Re-analysis of the primary efficacy data of the three phase III short-term studies (four com-
parisons in total, as for one three-arm trial each arm was considered separately v. placebo)
revealed an overall mean difference of −4.08 (95% CI −6.20 to 1.97, I2 = 0%, three studies,
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641 participants), suggesting that, in comparison with placebo,
esketamine may improve depressive symptoms reducing by 4
points the MADRS score (Fig. 1). Of the four comparisons
reported in Fig. 1, only one revealed a significant difference
between esketamine and placebo.
Pooling data on acceptability (dropouts due to any cause)
showed that esketamine was significantly less acceptable than pla-
cebo (relative risk (RR) = 1.63, 95% CI 1.02–2.60, I2 = 0%, three
studies, 711 participants). Re-analysis of data on the incidence
of dissociation showed that esketamine increased by seven times
the risk of this adverse effect over placebo, with approximately
25% of patients receiving esketamine who experienced severe dis-
sociation during treatment (Figs 2 and 3).
Re-analysis of the clinical data on esketamine submitted to the
FDA offered a unique opportunity to reflect on the evidence
supporting the licensing of this new agent and, more generally, to
critically appraise the approval process for new psychotropic drugs.
A first consideration refers to the efficacy of esketamine in
TRD. Of three randomised trials submitted to the FDA, only
TRANSFORM-2 was able to demonstrate the superiority of eske-
tamine over placebo, while the other two trials showed similar
mean differences in change scores without statistical significance.
Re-analysis of the three trials revealed an average reduction of 4
points at the MADRS, a scale that scores from 0 to 60.
Although this difference is statistically significant, its clinical
meaning seems very uncertain. The authors of the three studies
reported that a difference of at least 6.5 points at MADRS between
esketamine and placebo should be observed to make a claim of
clinical significance (Daly et al., 2019), based on the results of
phase II studies (Daly et al., 2017). This implies that an average
difference of 4 points may unlikely translate into a clinically
meaningful beneficial effect under real-world circumstances,
and additionally underlines a need for putting these results into
a wider context, as they do not match with the author expecta-
tions. It could be argued that the reduction in the MADRS
score from baseline to week 4 (−21.4 in the esketamine group
v. −17.0) showed in the TRANSFORM-2 trial was clinically sig-
nificant and higher as compared with other AD trials. However,
it should be noted that this is not related to the esketamine effect
itself, as a clinically important reduction in the MADRS score was
detected also in the placebo group. It is, instead, most likely to be
related to the high intensity of care received by patients in these
trials, as compared to real-world practice.
A second consideration is that this difference was calculated
against placebo, and not against an active comparator, such as,
for example, a fixed-dose combination of olanzapine and
fluoxetine, which is a licenced treatment in the USA for TRD.
Interestingly, the FDA accepted studies that did not compare
esketamine against the only available FDA-licensed gold-
standard. Moreover, other treatment combinations, which might
have been used as pragmatic control conditions, are often
employed in clinical practice for TRD (Sanacora et al., 2017;
Kim et al., 2019), but, according to the FDA, a demonstration
of efficacy against placebo is enough to grant a marketing author-
isation. A similar regulatory requirement is followed in Europe by
the European Medicines Agency (EMA). We argue that this regu-
lation is a real disservice as it allows the marketing of new drugs
that may be less effective, or more harmful, than others already in
use.
A third consideration is the extremely rapid onset of effect
observed in TRANSFORM-2. One might wonder whether this
effect means that esketamine was successful in rapidly correcting
an underlying brain abnormality, which clinically was observed as
a rapid improvement in depression scores or, rather, that esketa-
mine just modified some brain processes that impacted the
depression scores, as many psychoactive substances are able to
induce. This possibility, known as a drug-centred model, suggests
that drugs may produce a global state characterised by a range of
physiological and psychological alterations. These alterations are
likely to interact with the symptoms of mental disorders in
ways that may sometimes be beneficial (Moncrieff, 2018). The
rapid changes induced by esketamine make the drug-centred
model particularly plausible.
For esketamine, understanding whether this rapid change in
depression scores is due to an improvement of depression or
just to a temporary effect of the drug on some brain mechanisms
is of paramount relevance, as depression is a recurrent condition
(NICE, 2018), and TRD is a particularly severe form of depression
with symptoms persisting over long periods of time. It would be
important to know if this acute effect is maintained in the long-
term. For esketamine, however, long-term data are completely
lacking. We know from SUSTAIN-1 that participants who discon-
tinue esketamine after improvement with AD + esketamine are
more likely to relapse in comparison with those who do not dis-
continue (Daly et al., 2019; Kim et al., 2019). However, it is well-
known that this type of design tends to overemphasise the efficacy
of maintenance treatment, as the comparison group is at
extremely high risk of relapse, considering that treatment is
abruptly stopped soon after improvement (Paykel, 2001;
Pringsheim et al., 2016; NICE, 2018). Moreover, the high rate
of rapid relapses observed after just 2 weeks from discontinuation
might be interpreted as particularly worrisome, as it may suggest
Table 1. Characteristics of the three short-term esketamine efficacy trials submitted to the FDA
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MADRS, Montgomery–Asberg Depression Rating Scale; TRD, treatment-resistant depression; AD, antidepressant.
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that the abnormal brain state induced by esketamine has caused
rebound symptoms when suspended.
Additionally, the target population of withdrawal trials such as
SUSTAIN-1 is different from the population recruited in efficacy
short-term trials, where participants suffering from acute depres-
sion are recruited. As a consequence, generalizing results from a
withdrawal trial to patients with a current depressive episode is
difficult (Guyatt et al., 2008; Post et al., 2013), and extrapolating
efficacy in the long-term seems very problematic.
Methodologically, this is the first time that the FDA Division of
Psychiatry Products considered a randomised withdrawal trial
as one of the two adequate and well-controlled trials comprising
substantial evidence of effectiveness, as noted by Kim et al. in a
recent paper (Kim et al., 2019).
Fourth, although the FDA emphasised that the safety of esketa-
mine was the main concern given the well-known risks associated
with ketamine (FDA, 2019), studies showing that esketamine is less
risky than ketamine are lacking. Before approval, the FDA commit-
tee wrote in its documentation that ‘data on safety of ketamine may
be considered relevant to discussions regarding the safety of eske-
tamine. […] The risks of abuse and associated harms are important
considerations in determining appropriate risk mitigation strategies
and post marketing surveillance for esketamine, if approved’ (FDA,
2019). Consequently, after esketamine approval, the FDA deter-
mined that a Risk Evaluation and Mitigation Strategy (REMS) (a
drug safety programme required medications with serious safety
concerns) was needed to help ensure that the benefits of the
drug outweigh its risks. We argue that this implies approval with-
out knowledge of the potential negative consequences of esketa-
mine prescribing.
What can be extrapolated from the data submitted to the FDA,
however, is that esketamine showed a significant worse acceptabil-
ity profile as compared to placebo, with a higher proportion of
participants dropping-out. This performance seems different
than that of ketamine, as a recent Cochrane review found no dif-
ference between ketamine and placebo in terms of acceptability
(odds ratio (OR) 1.90, 95% CI 0.43–8.47; I2 = 24%; five studies,
139 participants) (Caddy et al., 2015). Indirectly, these results
pose some concerns on the overall acceptability of esketamine,
suggesting that it may be even worse than ketamine.
Additionally, the FDA reported that the safety concerns for
esketamine, for which a REMS was planned, are misuse, abuse,
dissociation and sedation (FDA, 2019; Kim et al., 2019), which
are known adverse effects of ketamine. During the trials, no
misuse or abuse was observed, but this was due to the fact that
esketamine was administered under strict medical supervision
Fig. 1. Mean difference between esketamine and placebo at day 28 (study endpoint) measured with the Montgomery–Asberg Depression Rating Scale (MADRS).
Fig. 2. Acceptability of esketamine v. placebo at day 28 (study endpoint), measured as drop-outs due to any cause.
Fig. 3. Risk of dissociation of esketamine v. placebo, measured as the proportion of patients experiencing this adverse effect.
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(at least 2 h), and only in highly specialised centres. For dissoci-
ation, re-analysis of the three efficacy trials revealed that the
risk of this adverse event was almost seven times higher in the
esketamine group as compared with placebo, with approximately
25% of patients experiencing severe dissociation during acute
treatment with esketamine. Again, we argue that further evidence
on safety is urgently needed, given these preliminary signs sug-
gesting that esketamine may not be safer than ketamine.
The example of esketamine shows that current rules governing
the registration of new psychotropic drugs are based on the con-
cept of absolute efficacy, which implies that a difference against
placebo, and not against an active comparator, makes a new inves-
tigational product eligible for registration. We suggest that the
concept of absolute efficacy should be replaced by the concept
of added value, which implies that evidence from studies compar-
ing an investigational product with an active comparator should
guide the drug approval process. We have additionally proposed
that the evaluation process of psychotropic medicines should be
complemented with regulatory meta-analyses of all relevant clin-
ical studies to define their efficacy and tolerability profile (Barbui
et al., 2017). Based on the results of regulatory meta-analyses,
regulatory authorities may develop a more systematic approach
to summarise the beneficial and harmful effects of new psycho-
tropic drugs. Also, for esketamine, a number of other studies
could have been evaluated, and the FDA itself reported that in
other studies, six suicides happened and all of them were in the
esketamine arm (FDA, 2019; Schatzberg, 2019). Excluding these
data from the approval process could lead to misleading conclu-
sions on safety, as recently pointed out by Schatzberg (2019).
Although the important limitations of the evidence base, eske-
tamine was labelled as a breakthrough therapy for TRD. The strat-
egy to approve it as REMS could help addressing some safety
issues, but this will require a long time and exposure of many per-
sons with depression to this new agent. Considering the explana-
tory nature of existing studies, large pragmatic trials are urgently
needed to better define the place in therapy of esketamine, aiming
to clarify if there is more than just smoke and mirrors.
Finally, we argue that the EMA should take into due account
all these critical issues when assessing the marketing authorisation
of esketamine for Europe, and, more broadly, we call for a radical
change of current regulatory rules for psychotropic drug approval.
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